Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCSBusiness Wire • 12/11/25
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?Zacks Investment Research • 12/03/25
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer SymposiumBusiness Wire • 11/24/25
EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott LaboratoriesGlobeNewsWire • 11/24/25
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXASBusiness Wire • 11/22/25
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Exact Sciences Corporation (NASDAQ: EXAS)GlobeNewsWire • 11/20/25
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)GlobeNewsWire • 11/20/25
Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and MoreInvestopedia • 11/20/25
Shareholder Alert: The Ademi Firm investigates whether Exact Sciences Corporation is obtaining a Fair Price for its Public ShareholdersPRNewsWire • 11/20/25
EXAS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Exact Sciences Corporation is Fair to ShareholdersBusiness Wire • 11/20/25
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer testMarket Watch • 11/20/25
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact SciencesReuters • 11/20/25
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segmentsPRNewsWire • 11/20/25